Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Sweden

Marie Skłodowska-Curie Action · Running

RAMP-UP Regenerative Medicine and Advanced Medicinal Therapeutic Products United for PhD excellence

Coordinator
Lunds Universitet, Sweden
Runs
1 August 2026 to 31 July 2031
Status
Running
EU funding
€8.3m
Total cost
—
Partners
28 organisations in 7 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101216514

What the project is doing

In the project's own words, from its summary on CORDIS.

The RAMP-UP program (Regenerative Medicine and Advanced Therapy Medicinal Products - United for PhD Excellence) is an international doctoral program initiative by Lund University (LU), Sweden, and three implementing partners: Leiden University Medical Center (LUMC), Netherlands; Technical University of Denmark (DTU); and Hannover Medical School (MHH), Germany. The aim is to create a high-quality international and interdisciplinary Doctoral Programme (DP), supported by about 30 associated partners, composed of leading companies, regulatory and health agencies representing the whole value chain of regenerative medicine and Advanced Therapy Medicinal Products (ATMPs) research.

The objectives of RAMP-UP are to:(i) Establish a collaborative, innovative, interdisciplinary, and united DP in regenerative medicine and ATMPs to train skilled professionals across the entire value chain of ATMPs.(ii) Create a European ATMP ecosystem for education in which academia, health care, regulatory agencies, and industry sectors come together to secure a leading international position in the field to the benefit of society.(iii) Propel the implementation and patient access to ATMPs in Europe, bridging the gap from bench to clinic.

This program comprises 55 Doctoral Fellows (DF) and represents a total budget of more than 32.5 M€, of which 75% is covered by the RAMP-UP partners, enabling the acceleration of advanced therapies from the bench to patients.

Topics

Who is involved

OrganisationCityCountryRole
Lunds UniversitetLundSwedenCoordinator
Miltenyi Biotec BV & Co KgBergisch GladbachGermanyAssociatedpartner
Bioneer A/sHoersholmDenmarkAssociatedpartner
Medicon Valley Academy F.m.b.a. ForeningKobenhavn SDenmarkAssociatedpartner
Novo Nordisk A/sBagsvaerdDenmarkAssociatedpartner
Novo Nordisk FondenHellerupDenmarkAssociatedpartner
Eurordis - Rare Diseases EuropeParisFranceAssociatedpartner
UAB Memel BiotechKlaipėdaLithuaniaAssociatedpartner
Centre for Ethics and HealthDen HaagNetherlandsAssociatedpartner
Koninklijke Nederlandse Akademie Van Wetenschappen - KnawAmsterdamNetherlandsAssociatedpartner
Netherlands Center for the Clinical Advancement of Stem Cell & Gene Therapies BVLeidenNetherlandsAssociatedpartner
Acousort ABLundSwedenAssociatedpartner
Asgard Therapeutics ABLundSwedenAssociatedpartner
Biolamina ABSundbybergSwedenAssociatedpartner
Ccrm Nordic ABMolndalSwedenAssociatedpartner
Cytiva Testa Center ABUppsalaSwedenAssociatedpartner
Ihe, Institutet for Halso- Och Sjukvardsekonomi AktiebolagLundSwedenAssociatedpartner
Lakemedelsindustriforeningens Service AktiebolagStockholmSwedenAssociatedpartner
LakemedelsverketUppsalaSwedenAssociatedpartner
Magle Chemoswed Holding ABMalmoSwedenAssociatedpartner
Medicon Village Innovation ABLundSwedenAssociatedpartner
Northx Biologics Matfors ABMatforsSwedenAssociatedpartner
Region SkaneKristianstadSwedenAssociatedpartner
Re:Lab ABVimmerbySwedenAssociatedpartner
Smile Venture Hub ABLundSwedenAssociatedpartner
Xintela ABLundSwedenAssociatedpartner
Lentitek LtdEdinburghUnited KingdomAssociatedpartner
Stemcell Technologies UK LtdCambridgeUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI